When Seeking ‘Breakthrough’ Status, Beware Of Manufacturing Changes
Clinical data supporting a designation request should come from a product under development, not from a study using an earlier formulation, CBER reps say. Rolling submissions help ensure that potential manufacturing and facility concerns are identified early.
You may also be interested in...
US FDA's Acting Orphan Products Development Director Has Gene Therapy Background
Ilan Irony will take over as acting director of the Office of Orphan Products Development later this month.
Breakthrough's Achilles Heel: Alexion’s Newly Acquired Kanuma Delayed By Manufacturing
FDA extends the PDUFA date for enzyme replacement therapy by three months so agency can review chemistry, manufacturing and controls information; another drug, Strensiq, is also pending at FDA without any action.
Accelerated Approval Conversion Could Mean ‘Breakthrough’ Loss
Sponsors of ‘breakthrough therapy’-designated investigational oncology products may need to identify a niche subpopulation that remains underserved when a competing product with accelerated approval in the same indication completes confirmatory trials.